The gastric H,K ATPase as a drug target: past, present, and future
about
Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infantsThe gastric HK-ATPase: structure, function, and inhibitionAcid-base transport in pancreas-new challengesActive detergent-solubilized H+,K+-ATPase is a monomerLong lasting inhibitors of the gastric H,K-ATPaseThe renal H+-K+-ATPases: physiology, regulation, and structureH+/K+-ATPase inhibitors: a patent review.Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitizationReview article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.Protonated form: the potent form of potassium-competitive acid blockersProton Pump Inhibitors Inhibit Pancreatic Secretion: Role of Gastric and Non-Gastric H+/K+-ATPases.The Significance of Variceal Haemorrhage in Ghana: A Retrospective Review.Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat modelSecretagogue stimulation enhances NBCe1 (electrogenic Na(+)/HCO(3)(-) cotransporter) surface expression in murine colonic cryptsPharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pyloriRecent advances in the molecular and functional characterization of acid/base and electrolyte transporters in the basolateral membranes of gastric and duodenal epithelial cells.Acid peptic diseases: pharmacological approach to treatment.Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Privileged Electrophile Sensors: A Resource for Covalent Drug Development.Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.Computational insights into the interaction mechanism of triazolyl substituted tetrahydrobenzofuran derivatives with H(+),K(+)-ATPase at different pH.Pancreatic bicarbonate secretion involves two proton pumps.Functional coupling of chloride-proton exchanger ClC-5 to gastric H+,K+-ATPaseE2P state stabilization by the N-terminal tail of the H,K-ATPase beta-subunit is critical for efficient proton pumping under in vivo conditions.Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects.Functional association between K+-Cl- cotransporter-4 and H+,K+-ATPase in the apical canalicular membrane of gastric parietal cells.Molecular mechanism and functional consequences of lansoprazole-mediated heme oxygenase-1 induction.Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6.Functional significance of E2 state stabilization by specific alpha/beta-subunit interactions of Na,K- and H,K-ATPase.Fluorescent Visualization of Cellular Proton Fluxes.Gastric Volume and Its Relationship to Underlying Pathology or Acid-suppressing Medication.In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.2-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol, a benzimidazole derivative, inhibits T cell proliferation involving H+/K+-ATPase inhibition.Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal--An In vitro Study.Ion Motive ATPases: P-type ATPases
P2860
Q24186815-D5C50F95-1193-4888-91AC-812A551D1B81Q24612375-9E93AD69-F151-43C9-B2B3-66E91DA6815BQ26998861-97635FDF-616D-41F7-B071-1A88D122E21BQ28276805-E15C11B3-B986-4072-83AC-58B90290DD74Q28299927-E172788A-8D0C-43F2-B976-1D9CA404C7C2Q33589092-E2CB3792-6D66-4FAA-B6C5-6F60C176549CQ34315036-60BA687D-E5A2-43EB-8180-8E3CACC787BFQ34394258-2835D5BC-CA1A-41A0-881F-EC7376FC4C20Q34965332-1104EE25-5A12-4307-A300-55F67041E950Q35171617-A1A54071-F20B-4E81-901F-6EEBBF3396E6Q35636415-79659BB6-E495-44A1-8A50-29FBCCFFE52DQ36365415-D4D6EB94-0010-4D7B-885E-DCC5CC82DC4FQ37001665-5861EA6B-8A4F-4C9F-BEDC-BCDA2D86DC0EQ37174848-FE8BBC78-F404-4C46-8B08-DB9FA44C138BQ37201668-B0219BCB-3309-4ACF-9C8C-ABB7ADE4062FQ37717739-C7EC5198-AC68-4E4B-B6F9-B0E9871E015EQ37913063-F00D256B-B005-4E80-B1FC-40913CF2E311Q38091317-AF0E5079-AB42-40F8-8B79-A9687FB0B235Q38415822-B670A4F6-2542-4C10-B6C8-322B55936BABQ38710055-98C468CA-417A-421F-BC08-B39E55A83C75Q38825937-C1D79C32-0A03-4215-86C5-7707C2FE76E5Q39445097-D864F698-D012-42CC-952A-6E7966241B91Q39746768-762BC05F-68B0-457C-BEC4-A45166BBA354Q40212184-A88414AD-B1F3-4616-9A7A-C0EE1886753BQ41556981-366DEA7D-21DB-4B7D-B228-A54FD96ABF0FQ41872254-09CDE83E-3762-42E6-B53A-60CF0ABB3267Q42056103-19DA2487-4972-4C4B-87AD-FA4609F7AF8FQ42364580-A7158944-83DE-4836-8BB4-141F9D8F6A2FQ42444367-BCA0175A-8C61-4F66-BE04-437F93319EAEQ42560063-E2DDEC50-5416-438C-97DB-C4D1B504F737Q42969515-7DCA1798-B03B-4D7D-A147-3BE3D76E9E92Q43270261-0A207798-67F4-4C1A-9928-9A8BBC8ED72BQ43457054-36D34E63-2918-4930-8CF2-78C8D7CBD057Q46209261-6C45531C-38B2-4526-8602-A37F07B744EFQ46766536-089B193B-B64C-448C-8FBB-4A69145F9A16Q47163832-A73FF835-6437-41A5-91CB-028AAA2FA822Q51642470-6B7CE27D-456C-4ECE-B85A-AD6F3D28432DQ53008503-FE3FFC26-8149-491D-AA82-B34FA340E768Q53402835-B159F85D-A5D6-43B1-94F9-985C2618B742Q57320170-879019B0-F771-4524-B7C6-FADE34D626FC
P2860
The gastric H,K ATPase as a drug target: past, present, and future
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The gastric H,K ATPase as a drug target: past, present, and future
@ast
The gastric H,K ATPase as a drug target: past, present, and future
@en
The gastric H,K ATPase as a drug target: past, present, and future
@nl
type
label
The gastric H,K ATPase as a drug target: past, present, and future
@ast
The gastric H,K ATPase as a drug target: past, present, and future
@en
The gastric H,K ATPase as a drug target: past, present, and future
@nl
prefLabel
The gastric H,K ATPase as a drug target: past, present, and future
@ast
The gastric H,K ATPase as a drug target: past, present, and future
@en
The gastric H,K ATPase as a drug target: past, present, and future
@nl
P2093
P2860
P1476
The gastric H,K ATPase as a drug target: past, present, and future
@en
P2093
George Sachs
Jai Moo Shin
Keith Munson
Olga Vagin
P2860
P304
P356
10.1097/MCG.0B013E31803233B7
P407
P433
Supplement 2
P478
41 Suppl 2
P577
2007-07-01T00:00:00Z